DYRK1A Shapes Pancreatic Tumor Immune Signaling
Researchers report that the DYRK1A protein regulates secreted factors that influence the pancreatic cancer tumor microenvironment.
Updated on Nov. 1, 2026 in Cancer
Researchers reported that DYRK1A regulates secreted factors that shape the pancreatic cancer tumor microenvironment. The findings were drawn from secretome profiling of cancer cells and cancer-associated fibroblasts.
Why it matters
Pancreatic ductal adenocarcinoma has a tumor microenvironment that helps cancer cells migrate and evade immune responses, and identifying the signals that drive this behavior may point to new treatment targets. The work suggests DYRK1A acts on both cancer cells and their supporting fibroblasts.
Quantitative mass spectrometry secretome profiling showed that DYRK1A inhibition reduced CCL2, CCL5, and CSF-1 secretion in cancer cells and CXCL12 secretion in cancer-associated fibroblasts relative to controls. Whether these laboratory secretion changes produce comparable effects inside living tumors has not been established in the findings.
The details
Conditioned media from DYRK1A-depleted cancer cells and from DYRK1A-depleted cancer-associated fibroblasts each impaired the migration of monocytes and myeloid-derived suppressor cells. Combining the DYRK1A-regulated proteins from both cell compartments highlighted categories linked to immune infiltration and cell-cell interactions.
Big Picture
Earlier work showed DYRK1A promotes pancreatic ductal adenocarcinoma growth by stabilizing c-MET inside cancer cells. The new findings extend that account by showing DYRK1A also controls secreted signals from cancer-associated fibroblasts that shape the surrounding tumor environment.
At this stage the findings concern laboratory cell models rather than treatments available to patients. Any future therapy targeting DYRK1A would require clinical testing before it could affect how pancreatic cancer is managed.
The takeaway
Targeting the signals that tumors and their supporting cells send to one another may be a route to slowing pancreatic cancer spread, though that remains an early research question.
Further reading
Explore more on Cancer research and tumor biology across our health coverage.
Source note: This article includes information reported by Nature.
